BPC-157
Body Protective Compound-157; pentadecapeptide BPC 157; Bepecin; PL 14736; PL-10
Access and compounding status raise extra safety and legal questions.
A lab-made peptide derived from a protein found in human stomach fluid that has shown healing effects across multiple body systems -- gut, tendons, muscles, nerves, and blood vessels -- in animal studies. Human clinical evidence is very limited (only small safety studies have been published), and the FDA currently restricts its availability through compounding pharmacies while more safety data is gathered.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
CRITICAL LIMITATION: No systematic human safety data exists. All listed effects are extrapolated from a 2-patient IV pilot study (PMID 40131143) and uncontrolled community reports. The true side effect profile is unknown. BPC-157 exhibits a favorable safety profile in preclinical studies with no evidence of toxicity, immunogenicity, or serious adverse effects across multiple animal species (mice, rats, rabbits, dogs). The 2-patient IV pilot study (10-20 mg, far above typical doses) reported no treatment-related adverse events (PMID: 40131143). No serious adverse events or dose-limiting toxicities have been reported in any setting. Community-reported side effects (injection site reactions, nausea, dizziness) occur at estimated 5-10% rates but are based on anecdotal reports, not controlled studies. No evidence of tolerance development or withdrawal effects. The FDA has flagged potential immunogenicity risk due to peptide nature, aggregation, and impurities in compounded products. Important caveat: the absence of reported serious adverse events may reflect extremely limited human exposure rather than true safety.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-10]